1. Home
  2. CMND vs GNPX Comparison

CMND vs GNPX Comparison

Compare CMND & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CMND
  • GNPX
  • Stock Information
  • Founded
  • CMND 2017
  • GNPX 2009
  • Country
  • CMND Canada
  • GNPX United States
  • Employees
  • CMND N/A
  • GNPX N/A
  • Industry
  • CMND Biotechnology: Pharmaceutical Preparations
  • GNPX Biotechnology: Pharmaceutical Preparations
  • Sector
  • CMND Health Care
  • GNPX Health Care
  • Exchange
  • CMND Nasdaq
  • GNPX Nasdaq
  • Market Cap
  • CMND 6.0M
  • GNPX 6.1M
  • IPO Year
  • CMND N/A
  • GNPX 2018
  • Fundamental
  • Price
  • CMND $1.03
  • GNPX $0.30
  • Analyst Decision
  • CMND
  • GNPX Strong Buy
  • Analyst Count
  • CMND 0
  • GNPX 1
  • Target Price
  • CMND N/A
  • GNPX $10.00
  • AVG Volume (30 Days)
  • CMND 55.0K
  • GNPX 6.0M
  • Earning Date
  • CMND 03-13-2025
  • GNPX 05-13-2025
  • Dividend Yield
  • CMND N/A
  • GNPX N/A
  • EPS Growth
  • CMND N/A
  • GNPX N/A
  • EPS
  • CMND N/A
  • GNPX N/A
  • Revenue
  • CMND N/A
  • GNPX N/A
  • Revenue This Year
  • CMND N/A
  • GNPX N/A
  • Revenue Next Year
  • CMND N/A
  • GNPX N/A
  • P/E Ratio
  • CMND N/A
  • GNPX N/A
  • Revenue Growth
  • CMND N/A
  • GNPX N/A
  • 52 Week Low
  • CMND $0.95
  • GNPX $0.22
  • 52 Week High
  • CMND $2.30
  • GNPX $4.09
  • Technical
  • Relative Strength Index (RSI)
  • CMND 34.60
  • GNPX 39.82
  • Support Level
  • CMND $1.04
  • GNPX $0.22
  • Resistance Level
  • CMND $1.11
  • GNPX $0.41
  • Average True Range (ATR)
  • CMND 0.06
  • GNPX 0.06
  • MACD
  • CMND -0.00
  • GNPX -0.00
  • Stochastic Oscillator
  • CMND 10.07
  • GNPX 25.00

About CMND Clearmind Medicine Inc.

Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Share on Social Networks: